161 related articles for article (PubMed ID: 14716298)
1. Amplification and overexpression of E2F3 in human bladder cancer.
Feber A; Clark J; Goodwin G; Dodson AR; Smith PH; Fletcher A; Edwards S; Flohr P; Falconer A; Roe T; Kovacs G; Dennis N; Fisher C; Wooster R; Huddart R; Foster CS; Cooper CS
Oncogene; 2004 Feb; 23(8):1627-30. PubMed ID: 14716298
[TBL] [Abstract][Full Text] [Related]
2. E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer.
Oeggerli M; Tomovska S; Schraml P; Calvano-Forte D; Schafroth S; Simon R; Gasser T; Mihatsch MJ; Sauter G
Oncogene; 2004 Jul; 23(33):5616-23. PubMed ID: 15122326
[TBL] [Abstract][Full Text] [Related]
3. E2F3 is the main target gene of the 6p22 amplicon with high specificity for human bladder cancer.
Oeggerli M; Schraml P; Ruiz C; Bloch M; Novotny H; Mirlacher M; Sauter G; Simon R
Oncogene; 2006 Oct; 25(49):6538-43. PubMed ID: 16953223
[TBL] [Abstract][Full Text] [Related]
4. Nuclear overexpression of the E2F3 transcription factor in human lung cancer.
Cooper CS; Nicholson AG; Foster C; Dodson A; Edwards S; Fletcher A; Roe T; Clark J; Joshi A; Norman A; Feber A; Lin D; Gao Y; Shipley J; Cheng SJ
Lung Cancer; 2006 Nov; 54(2):155-62. PubMed ID: 16938365
[TBL] [Abstract][Full Text] [Related]
5. [Evaluation of potential target genes of the 6p22.3-amplicon in urinary bladder cancer].
Oeggerli M; Schraml P; Novotny H; Sauter G; Simon R
Verh Dtsch Ges Pathol; 2005; 89():219-24. PubMed ID: 18035695
[TBL] [Abstract][Full Text] [Related]
6. Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplification.
Hurst CD; Tomlinson DC; Williams SV; Platt FM; Knowles MA
Oncogene; 2008 Apr; 27(19):2716-27. PubMed ID: 18037967
[TBL] [Abstract][Full Text] [Related]
7. High-throughput tissue microarray analysis of 11q13 gene amplification (CCND1, FGF3, FGF4, EMS1) in urinary bladder cancer.
Zaharieva BM; Simon R; Diener PA; Ackermann D; Maurer R; Alund G; Knönagel H; Rist M; Wilber K; Hering F; Schönenberger A; Flury R; Jäger P; Fehr JL; Mihatsch MJ; Gasser T; Sauter G; Toncheva DI
J Pathol; 2003 Dec; 201(4):603-8. PubMed ID: 14648664
[TBL] [Abstract][Full Text] [Related]
8. TRIO amplification and abundant mRNA expression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer.
Zheng M; Simon R; Mirlacher M; Maurer R; Gasser T; Forster T; Diener PA; Mihatsch MJ; Sauter G; Schraml P
Am J Pathol; 2004 Jul; 165(1):63-9. PubMed ID: 15215162
[TBL] [Abstract][Full Text] [Related]
9. HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder.
Coogan CL; Estrada CR; Kapur S; Bloom KJ
Urology; 2004 Apr; 63(4):786-90. PubMed ID: 15072912
[TBL] [Abstract][Full Text] [Related]
10. Delineation of the 6p22 amplification unit in urinary bladder carcinoma cell lines.
Bruch J; Schulz WA; Häussler J; Melzner I; Brüderlein S; Möller P; Kemmerling R; Vogel W; Hameister H
Cancer Res; 2000 Aug; 60(16):4526-30. PubMed ID: 10969802
[TBL] [Abstract][Full Text] [Related]
11. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17.
Simonetti S; Russo R; Ciancia G; Altieri V; De Rosa G; Insabato L
Int J Surg Pathol; 2009 Jun; 17(3):198-205. PubMed ID: 19443884
[TBL] [Abstract][Full Text] [Related]
12. Amplification and overexpression of the ID4 gene at 6p22.3 in bladder cancer.
Wu Q; Hoffmann MJ; Hartmann FH; Schulz WA
Mol Cancer; 2005 May; 4(1):16. PubMed ID: 15876350
[TBL] [Abstract][Full Text] [Related]
13. Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome.
Foster CS; Falconer A; Dodson AR; Norman AR; Dennis N; Fletcher A; Southgate C; Dowe A; Dearnaley D; Jhavar S; Eeles R; Feber A; Cooper CS
Oncogene; 2004 Aug; 23(35):5871-9. PubMed ID: 15184867
[TBL] [Abstract][Full Text] [Related]
14. Methylation patterns of Rb1 and Casp-8 promoters and their impact on their expression in bladder cancer.
Malekzadeh K; Sobti RC; Nikbakht M; Shekari M; Hosseini SA; Tamandani DK; Singh SK
Cancer Invest; 2009 Jan; 27(1):70-80. PubMed ID: 19160091
[TBL] [Abstract][Full Text] [Related]
15. Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression.
Quentin T; Schlott T; Korabiowska M; Käthei N; Zöller G; Glaser F; Kunze E
Anticancer Res; 2004; 24(5A):2745-56. PubMed ID: 15517881
[TBL] [Abstract][Full Text] [Related]
16. Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status.
Maas S; Warskulat U; Steinhoff C; Mueller W; Grimm MO; Schulz WA; Seifert HH
Urology; 2004 Feb; 63(2):392-7. PubMed ID: 14972509
[TBL] [Abstract][Full Text] [Related]
17. Is quantitative real-time RT-PCR an adjunct to immunohistochemistry for the evaluation of ErbB2 status in transitional carcinoma of the bladder?
Amsellem-Ouazana D; Bièche I; Molinié V; Elie C; Vieillefond A; Tozlu S; Botto H; Debré B; Lidereau R
Eur Urol; 2006 Jun; 49(6):1035-42; discussion 1042-3. PubMed ID: 16466848
[TBL] [Abstract][Full Text] [Related]
18. Identification of CCND3 and BYSL as candidate targets for the 6p21 amplification in diffuse large B-cell lymphoma.
Kasugai Y; Tagawa H; Kameoka Y; Morishima Y; Nakamura S; Seto M
Clin Cancer Res; 2005 Dec; 11(23):8265-72. PubMed ID: 16322284
[TBL] [Abstract][Full Text] [Related]
19. Gains and overexpression identify DEK and E2F3 as targets of chromosome 6p gains in retinoblastoma.
Grasemann C; Gratias S; Stephan H; Schüler A; Schramm A; Klein-Hitpass L; Rieder H; Schneider S; Kappes F; Eggert A; Lohmann DR
Oncogene; 2005 Sep; 24(42):6441-9. PubMed ID: 16007192
[TBL] [Abstract][Full Text] [Related]
20. SOX4 expression in bladder carcinoma: clinical aspects and in vitro functional characterization.
Aaboe M; Birkenkamp-Demtroder K; Wiuf C; Sørensen FB; Thykjaer T; Sauter G; Jensen KM; Dyrskjøt L; Ørntoft T
Cancer Res; 2006 Apr; 66(7):3434-42. PubMed ID: 16585165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
